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Abstract
Background: Demographic projections suggest a major increase in non-communicable disease
(NCD) mortality over the next two decades in developing countries. In a climate of scarce
resources, policy-makers need to know which interventions represent value for money. The
prohibitive cost of performing multiple economic evaluations has generated interest in transferring
the results of studies from one setting to another. This paper aims to bridge the gap in the current
literature by critically evaluating the available published data on economic evaluations of NCD
interventions in developing countries.
Methods: We identified and reviewed the methodological quality of 32 economic evaluations of
NCD interventions in developing countries. Developing countries were defined according to the
World Bank classification for low- and lower middle-income countries. We defined NCDs as the
12 categories listed in the 1993 World Bank report Investing in Health. English language literature
was searched for the period January 1984 and January 2003 inclusive in Medline, Science Citation
Index, HealthStar, NHS Economic Evaluation Database and Embase using medical subheading terms
and free text searches. We then assessed the quality of studies according to a set of pre-defined
technical criteria.
Results: We found that the quality of studies was poor and resource allocation decisions made by
local and global policy-makers on the basis of this evidence could be misleading. Furthermore we
have identified some clear gaps in the literature, particularly around injuries and strategies for
tackling the consequences of the emerging tobacco epidemic.
Conclusion: In the face of poor evidence the role of so-called generalised cost-effectiveness
analyses has an important role to play in aiding public health decision-making at the global level.
Further research is needed to investigates the causes of variation among cost, effects and cost-
effectiveness data within and between settings. Such analyses still need to take a broad view,
present data in a transparent manner and take account of local constraints.
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The next two decades are predicted to see dramatic
changes in the health needs of the developing world.
Whilst developing nations are still struggling with the
unfinished agenda of communicable diseases (in particu-
lar HIV/AIDS, malaria and tuberculosis) a major increase
in NCD mortality is predicted, as depression, heart disease
and cancer replace infectious diseases as the leading
causes of disability and premature death [1]. The steep
projected increase in the burden of NCDs worldwide is
not only driven by demographic changes, but also by the
rapidly increasing numbers of people who smoke or who
are exposed to other risks such as obesity, physical inactiv-
ity and heavy alcohol consumption. Factors including
rapid urbanisation and industrialisation are implicated in
the increase in neuropsychiatric disorders such as depres-
sion and alcohol dependence.
Undoubtedly, estimates of the current and future burden
of disease have stimulated the recognition of the impor-
tance of NCDs [2]. However, while information on the
burden of disease can illustrate the magnitude of a dis-
ease, it provides no guidance in terms of how best to deal
with it [3,4]. If decisions are to be made about where to
direct scarce resources, policy-makers need to know which
of the available interventions to tackle these diseases are
the most efficient and equitable.
In 2000 WHO re-emphasised the role that cost-effective-
ness analysis can have in identifying the interventions
able to provide most health gain from available resources
[5]. Cost-effectiveness analyses have also been included in
sectoral allocation exercises for countries seeking health
sector loans from the World Bank. However, these have
occurred only in a limited number of countries and with
a limited number of interventions [6]. Hence there is an
urgent need to establish which interventions are cost-
effective in developing country settings. Given the expense
of such exercises, the capacity to undertake analyses and
the role of international and bi-lateral agencies in funding
the evaluation and provision of interventions, there is also
much interest in being able to generalise the models and
findings from economic evaluations across developing
countries.
Given the increasing importance of economic evaluation
as a decision-making tool, it is imperative that the quality
of evaluations undertaken is monitored. Two reviews of
the quality of studies aimed at parasitic and communica-
ble diseases found that few published economic evalua-
tions had been performed, diseases and geographical
areas had been neglected and for the most part the quality
of studies was poor [7,8]. However, the quality of existing
evaluations of NCD interventions in developing countries
has never been systematically evaluated, hence very little
is known about the existing evidence base. Although Jam-
ison et al. reviewed the available literature on NCDs in
1993, no systematic attempt was made to evaluate the
methodological quality of the studies [9].
This paper has three objectives: to critically appraise
approaches taken in costing and the assessment of out-
comes, as well as methods of analysis and interpretation;
to consider the quality of the evidence concerning the effi-
ciency of NCD interventions and its potential contribu-
tion to decision-making; and to examine the applicability
of best practice in economic evaluation of NCDs in devel-
oping country settings.
Methods
The review sought to identify published economic evalu-
ations of interventions aimed at NCDs in developing
countries. Developing countries were defined according
to the World Bank classification for low- and lower mid-
dle-income as having a gross national income of less than
$9,205 per capita. We defined NCDs as the 12 categories
listed in the 1993 World Bank report Investing in Health
(cancer, cardiovascular, diabetes, neuropsychiatric, nutri-
tional, oral health, digestive diseases, respiratory, sense
organ, congenital abnormalities, genitourinary, musko-
skeletal) plus unintentional and intentional injuries [10].
English language literature was searched for the period
January 1984 and January 2003 inclusive, in Medline, Sci-
ence Citation Index, HealthStar, NHS Economic Evalua-
tion Database and Embase using medical subheading
terms and free text searches (See Table 1). We also used
reviews of economic evaluations of NCD interventions [9-
11]. Finally, we contacted experts in the field for further
references. Since this was a review of the published litera-
ture we did not search the 'grey' literature.
Our first search yielded 273 items. After reviewing the
titles and abstracts to reject any from high-income coun-
tries, 61 articles appeared to match our inclusion criteria.
Table 1: Search strategy
1 Medline, HealthStar, PreMedline and PubMed
Thesaurus cost-benefit analysis [all subheadings] combined with thesaurus: Malignant Neoplasms, Cancer, Diabetes, Nutritional and 
endocrine, Neuropsychiatric, Sense organ, Cardiovascular, Respiratory, Digestive, Genitourinary, Musculoskeletal, Congenital abnormalities, Oral 
health, Injuries.
2 Medline, HealthStar, NEED, King's Fund Library database, Science Citation Index (SCZZ), Social Science Citation Index (SSCI), Embase (EMZZ)
Text searches: cost* and benefit*; cost* and effect*; and cost* and utility* in combination with the above diseasesPage 2 of 10
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(n = 29) were subsequently excluded because they were:
review articles, editorials or letters (n = 15); cost analyses
with no details on effects (n = 7); or cost-outcome analy-
ses and hence not full economic evaluations (n = 7) [12].
A set of review questions was developed based on Drum-
mond et al.'s checklist which covered background ques-
tions (e.g. country, disease, intervention) and technical
characteristics (perspective adopted, covering aspects of
cost, outcomes and types of analysis/interpretation) [12].
Results
Background characteristics
We identified 32 articles published in 19 journals between
the years 1984 and 2003 [13-44]. Most articles were pub-
lished in a country or regional based journal, e.g. East Afri-
can Medical Journal and the South African Medical Journal
rather than more general journals such as The Lancet. Cost-
effectiveness studies were the main study type (n = 23) fol-
lowed by cost minimisation (n = 8), cost utility (n = 1)
and cost-benefit analyses (n = 1). It is worth noting that
although several papers described themselves as cost-ben-
efit analyses, they were in fact cost-effectiveness studies
because health benefits had not been valued in monetary
units. Table 2 shows that the majority of studies were car-
ried out in Asia (n = 16) and sub-Saharan Africa (n = 14)
with only five considering the Americas.
Table 3 shows that the papers covered a broad range of
disease groups. The most common focus was nutritional
disorders (n = 8) followed by half the number of papers
on cardiovascular and neuropsychiatric diseases. Table 3
also shows that the majority of studies concentrated on
treatment (n = 23) rather than prevention (n = 8) or diag-
nosis (n = 7). Within this classification there was a range
of interventions. For example, interventions with a treat-
ment focus included the evaluation of a new drug or a sur-
gical technique (n = 9) and the management of a disease
such as diabetes or epilepsy in different settings (n = 6). Of
the eight studies which examined preventive strategies,
three examined nutritional interventions to prevent vita-
Table 2: Comparison between the number of papers published by region and regional estimates of the burden of non-communicable 
disease
Region Number of papers* % Burden of disease (hundreds of thousands of DALYs lost)** %
Sub-Saharan Africa 14 44% 1050 18%
Asia and other Islands 11 34% 1040 18%
Latin America and the Caribbean 4 13% 689 12%
India 3 9% 1714 29%
China 2 6% 1431 24%
Total 34 100 5924 100
* Some papers performed multiple analyses and/or used multiple sources of data etc. Therefore, the presentation of results may suggest that there 
are more than 32 papers, which is not the case.
**Source: World Development Report 1993 [10]
Table 3: Study focus
Focus Diagnosis Prevention Treatment Number of papers*
Nutritional 1 3 6 8
Cardiovascular 1 4 4
Neuropsychiatric 1 1 3 4
Cancer 3 1 1 3
Injury/Trauma 1 3 3
Digestive 1 2 2
Genitourinary 1 1 2
Respiratory 2 2
Sense organ 2 2
Congenital abnormalities 1 1
Diabetes 1 1
Muskoskeletal 1 1
Oral health 1 1
Other surgical 1 1
Number of Papers* 7 8 23
* Some papers performed multiple analyses. Therefore, the presentation of results may suggest that there are more than 32 papers, which is not 
the case. For this reason the sum of rows and columns does not always equal the number of papers.Page 3 of 10
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smoking strategies (both as part of a broader package of
interventions) and one study looked at legislation to pre-
vent road traffic injuries. Other examples included a
school based dental programme and a home-visiting
scheme for psychiatric patients. The seven studies with a
diagnostic focus included cancer screening interventions
(n = 3), and studies which examined the diagnosis of
sickle cell anaemia and renal failure (n = 2).
It was not possible to determine the source of funding for
eight studies. Where it was possible to deduce the source
of funding, public sponsorship was overwhelmingly the
most common (n = 23). Among public funding bodies
were national governments (n = 15); international organ-
isations such as the World Health Organization (WHO)
and the World Bank (n = 3) and non-governmental organ-
isations or charitable foundations (n = 2). Private support
from a pharmaceutical company was stated in one paper.
Technical characteristics
Perspective
Relatively few authors stated the perspective of their paper
explicitly. However it was possible to infer the perspective
of all papers after examining the costs included. The
health care provider was the perspective most often used
(n = 25). One study took the perspective of both the pro-
vider and patients, and one study examined patient costs
only. Any study that also included indirect costs or bene-
fits was defined loosely as having taken a societal perspec-
tive and, using this definition, five studies took this
perspective.
Costs
With one exception,[23] all studies in the review included
some direct health care provider costs, although the scope
of these varied enormously. Often authors simply
included the costs of the intervention(s) under study and
assumed all other costs (such as overheads) to be the
same. Other studies were more comprehensive and
included overhead costs and capital costs. Occasionally
the total cost of an intervention was cited but it was
impossible to determine what was included in the esti-
mate. Three papers explicitly considered donated inputs.
For the five studies that took a societal perspective, indi-
rect costs consisted of wage losses due to morbidity and
mortality and time spent seeking treatment.
Many studies used actual expenditure data (n = 17) as
their source of data. Seven studies used published sources
to generate cost estimates sometimes supplemented with
expert opinion. Two studies used expert opinion only.
Sometimes, however, it was not possible to see exactly
how costs were derived (n = 6).
The majority of studies (n = 17) appeared to use an 'ingre-
dients' costing approach where costs were broken down
between the main cost components such as vehicles, sala-
ries and consumables. Fewer (n = 5) used an 'activity'
based approach, by identifying specific tasks such as pro-
gramme and therapy costs. Two studies appeared to use
some combination of the two and it was not possible to
discern the approach for eight papers as only the final
total costs were provided. Regardless of the approach
taken, most papers (n = 21) presented aggregated cost
information so it was impossible to ascertain whether all
the previously identified costs had been measured. Only
seven studies provided details of resources consumed in
physical units, such as numbers of staff employed or time
spent on a particular activity.
Valuation of costs
The costs of donated inputs, such as people's time, was
generally valued using unskilled or minimum wage rates.
All of the studies used market prices of one form or
another to value the costs of interventions but none dis-
cussed the possibility that these prices may not fully
reflect the opportunity cost of resources. Currencies
included: US dollars (n = 12); UK pounds (n = 1) with the
remaining studies using local currencies (n = 16). In addi-
tion, three studies quoted costs in both US dollars and the
local currency. The possibility that exchange rates may not
always reflect the true economic costs and benefits of
importing and exporting was addressed by one study,
which noted the potential impact of local import duties
on equipment costs [21].
Consequences
Primary data were generated by epidemiological studies,
including experimental (i.e. randomised controlled trials)
and quasi-experimental (i.e. intervention versus control
but not randomised, or before-and-after) (n = 14) and
observational studies (n = 9). Studies using secondary
data (n = 9) generally used published data from other
studies and generated results using decision tree analysis
or other basic modelling techniques such as applying a
published mortality rate to the study population.
Papers presented a range of outcome measures ranging
from impact on process to final outcomes. Process (e.g.
length of stay, hospitalisation rate) or intermediate case-
specific outcome measures (e.g. number of cases of cancer
detected) were presented in every paper. The most fre-
quently presented final outcome measures were impact of
an intervention on morbidity e.g. cases prevented (n = 23)
and mortality e.g. deaths averted or life years gained (n =
8). Only one study used a measure of effects combining
quantity and quality of life (disability adjusted life years
(DALYs)), the calculation of which was based on local
(Nepalese) life expectancies, utility values derived in Can-Page 4 of 10
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treatment [29]. Finally, one study expressed outcomes in
terms of monetary units, by estimating the impact of cor-
recting iron deficiencies on the productivity of agricultural
workers [26].
Types of analyses and interpretation of results
The most frequently used summary measure for cost-
effectiveness and cost-utility analyses was average cost-
effectiveness ratios (n = 20). Three studies also examined
the additional costs and benefits associated with shifting
to a competing alternative using incremental analysis to
estimate incremental cost-effectiveness ratios. As cost-
minimisation analyses compare interventions that have
the same effect, the eight cost-minimisation analyses in
the review used either least cost or net savings as their
summary measure. The cost-benefit analysis used a bene-
fit/cost ratio as its summary measure.
The mean duration of interventions studied was 1.6 years
(range: 1 month – 5 years) and whilst the mean analytic
horizon was longer at 3.6 years (range: 1 month – 33
years), the majority of papers (n = 18) analysed costs and
effects for one year or less. It was impossible to ascertain
the time horizons for three papers. Given that the major-
ity of studies adopted an annual time horizon, discount-
ing was effectively ignored by most papers. However, of
the 11 papers with differential timing, only three papers
used a discount rate; two papers used a rate of 3 per cent
and one used a rate of 10 per cent.
Less than half (n = 14) of the papers undertook any kind
of sensitivity analysis to assess the robustness of their find-
ings to assumptions about input parameters or model
structure. Of these, one-way sensitivity analysis was the
most common technique (n = 12). Two studies used
threshold analysis and one performed a multi-way analy-
sis. None considered the structure of the model. Some
studies (n = 5) provided reasons for the choice of sensitiv-
ity analysis. For instance, one study stated that there were
uncertainties about most of the values used to calculate
the cost-effectiveness ratios [27]. Another indicated that
data in the baseline analysis that had to be estimated was
subsequently tested using sensitivity analysis [25]. A fur-
ther study examined the impact of bias introduced by
non-randomisation of the study group [33]. More often,
however, studies stated that a sensitivity analysis was
undertaken to confirm the 'robustness of the results' but
justifications for the particular methods of analysis or the
choice of variables to alter was not always clear.
Only four studies (13% of papers) explicitly mentioned
the likely impact of implementing the intervention on the
annual total health budget. Another eight mentioned
issues of affordability but only in very brief terms, for
example by noting simply that the available budget
should be taken into account (but without providing any
details), or by questioning the sustainability of a novel
service such as a mobile cervical cytology screening service
where there are already established health services [16].
The costs and effects of interventions and their alterna-
tives can potentially vary greatly from one context to
another. The extent to which the results or models from
economic evaluations are generalisable to other settings is
thus important to consider. Although many papers (n =
13) made an attempt to address this issue, efforts were
largely confined to simply stating the limitations of the
study, such as whether randomisation was employed or
noting one or two facts about the study site which might
limit generalisability to other contexts. One paper argued
that the result for the country in question (Nepal) might
be more expensive than other countries because of high
transportation costs due to the difficult terrain [27].
Another study from Sri Lanka argued that the presence of
higher socio-economic groups and greater private medical
insurance coverage might limit the generalisability of their
results [31]. Overall, of the 13 papers that mentioned gen-
eralisability issues, five stated that results were not gener-
alisable to other settings while only one explicitly claimed
that the methods and interpretation should be generalisa-
ble to other settings [22].
Discussion
We could identify only 33 economic evaluations aimed at
NCDs published between 1984 and 2003 with 26 of these
published in the years following the 1993 World Develop-
ment Report. It is roughly equivalent to one study per four
developing countries and is less than a quarter of the
number found in a similar review for communicable dis-
eases [7]. However, we do recognise the following limita-
tions: the search was confined to English language
publications only; and it excluded unpublished and 'grey'
literature domain. On the other hand, we wanted to cap-
ture material that was likely to be relatively easily accessi-
ble to decision-makers in developing countries.
The above notwithstanding, we believe our findings rep-
resent an alarming paucity of evidence and reflect the con-
cerns of others in the field that there is a gap in NCD
research in developing countries. Mendis et al suggest that
"fragile research capacity, inadequate financial invest-
ment, langauge barriers and exclusions of journals edited
in developing countries in MEDLINE are some of the fac-
tors that probably contribute to this situation" [45]. We
are inclined to agree with this view.
Viewing the proportions of papers alone in relation to the
burden of disease suggest that injuries are particularly
under-represented relative to nutritional disorders (seePage 5 of 10
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Asia are over-represented relative to India and China in
terms of the number of studies published (see Table 1).
However, this takes no account of the expenditure on
interventions in these areas and the disease categories
mask gaps in specific intervention areas. For example,
only two studies [17,42] looked at anti-smoking interven-
tions and in both cases these interventions were not the
main focus of the analysis. This is despite predictions of
an emerging tobacco epidemic influencing both cardio-
vascular diseases and cancer. Similarly, we could find only
three studies aimed at injury or trauma [21,22,36] and
only one of these [22] looked at prevention rather than
treatment. Overall, it seems that the existing evidence base
from developing countries is very unlikely to be able to
challenge effectively any resource allocation decisions
made on the basis of burden of disease estimates without
a great deal more investment in the number of economic
evaluations across countries and health interventions.
The studies reviewed here raise a further question con-
cerning the extent to which we might expect differences in
the number of studies aimed at non-communicable dis-
eases compared to communicable diseases in developing
countries. There are several reasons why this might be the
case. First, inevitably, focus at the national and interna-
tional level remains on the unfinished agenda of commu-
nicable disease. Second, many NCD interventions such as
cancer prevention and screening are complex and cur-
rently still unaffordable in developing countries. Equally,
many cost-effective NCD interventions emphasise life
style and preventive interventions, but these tend to be
aimed at older people. Arguably this group are not given
as high a priority by funders of evaluations compared to
the target group of many communicable disease interven-
tions: children and pregnant women. These reasons go
some way to explain the paucity of data and emphasise
why there is perhaps a greater need to increase the meth-
odological rigour of the few studies that are undertaken in
this area.
However, to simply invest in increasing the number of
economic evaluations requires careful consideration as
our review has highlighted a number of concerns with the
existing evidence base that resonate with the findings of
other reviews [7,46-48]. At times studies are opaque, miss
opportunities to facilitate decision-making and give
almost no consideration to the generalisability of results
or models to other countries. We explain our reasoning
for each below along with the implications.
Too many studies are opaque
The basic tasks of any economic evaluation are to identify,
measure, value and compare the costs and consequences
of the alternatives being considered. Ideally, utilisation
data should be presented alongside average cost data in
order for readers to see how total costs are constructed
[49]. However the lack of transparency in many of the
studies meant it was impossible to ascertain what authors
had actually done. For example, six studies did not cite the
source of cost data and in many studies price and quantity
data were aggregated so it was not always clear whether all
appropriate costs were measured and valued. In others it
was not clear whether the full range of costs were consid-
ered because inadequate descriptions of the range of alter-
natives were provided. Relatively few studies considered
the possibility of costs falling on patients and their car-
egivers, even though these costs are potentially important
and their inclusion could change overall recommenda-
tions [50].
The main implication of these findings is that the internal
validity of many papers could not be judged. Should deci-
sion-makers therefore not use such results? Whilst we may
want to conclude 'yes', given the paucity of data it seems
unlikely that there are many good alternatives and it may
be better to have partially informed estimates or adjusted
estimates than no estimates at all.
Few findings are interrogated rigorously for their own 
setting
We found little critical examination of findings in relation
to the study site. Over half of papers undertook no sensi-
tivity analysis at all. In reality, however, every evaluation
will contain some degree of uncertainty or imprecision.
Differences in the perspective of an analysis, alternative
methodological approaches or assumptions used to
derive estimates of costs and outcomes, may have dra-
matic effects on the results. Of those that did undertake
Table 4: Study focus and burden of disease
Proportion of 
papers with 
focus
Proportion of NCD 
DALYs in low and 
middle income 
countries, 1990*
Nutritional 23% 6%
Cardiovascular 11% 16%
Neuropsychiatric 11% 18%
Cancer 9% 9%
Injury/Trauma 9% 28%
Digestive diseases 6% 5%
Genitourinary 6% 2%
Respiratory 6% 7%
Sense organ 6% 2%
Congenital abnormalities 3% 3%
Diabetes 3% 1%
Muskoskeletal 3% 2%
Oral health 3% 1%
* Source: World Health Report 1999 [57] (Annex Table 3). 
Expressed as a proportion of DALYs attributable to: NCDs, 
nutritional deficiencies and injuriesPage 6 of 10
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method used, with only two studies developing this to a
threshold analysis. Whilst one-way sensitivity analysis is
helpful in understanding the impact of assumptions
about individual variables, by itself it is an under-estimate
of how uncertain the estimated overall cost-effectiveness
ratio actually is. Various forms of multi-way sensitivity
analysis offer a relatively easy route to a qualitative explo-
ration of the uncertainty concerning parameter inputs
[51]. with statistical analyses available for calculating con-
fidence intervals/ellipsoids [52,53]. Finally, it was also
notable that no paper questioned or examined the impact
of the structure behind, or process of developing, the
implicit or explicit models of cost-effectiveness.
Opportunities to facilitate decision-making are often lost
A critical choice in the application of economic analyses
to aid resource allocation is the choice of outcome meas-
ure. All studies used some form of process or intermediate
case-specific units as a measure of effect. While this is
acceptable for assessing technical efficiency (which is con-
cerned with how best to meet a given objective at least
cost) it does not help in choosing how to allocate
resources across different programmes with different out-
comes because like cannot be compared with like. It does
not facilitate a sectoral perspective to be taken where the
costs and effectiveness of all possible interventions are
compared in order to select the mix that maximises health
or some other objective function for a given set of resource
constraints. This problem is compounded given the lack
or transparency of reporting the source of data and disag-
gregated effects, as other evaluators are unable to make
the link between disease averted and gains in health or
welfare. If, as predicted, the burden of NCDs rises in rela-
tion to the already considerable burden of communicable
diseases then choices will need to be made between
options across the disease spectrum.
Thus the challenge is for economic evaluations to use out-
come measures that facilitate comparisons across the
health sector. Deaths averted or life years gained, pre-
sented in 25% of papers, were the main outcome meas-
ures comparable across diseases and health interventions.
However, as NCDs rise in relation to communicable dis-
ease, measuring only deaths averted may underestimate
health gain from interventions to prevent or treat NCD as
a significant impact may be realised in terms of quality of
life and not only quantity of life.
The scant attention paid to issues of affordability and sus-
tainability are also worrying. In particular in developing
countries, where significant proportions of inputs may be
imported or donated, it is important to estimate the cur-
rent and potential future financial costs. Very few con-
trasted the economic costs of introducing a new
programme on overall health expenditure or considered
separately the cost of introducing and running a new pro-
gramme.
Generalisability
Ultimately, a good study should help the user interpret
the results for use in other settings. However, the majority
of papers avoid considering the generalisability of their
results and models or simply state that their results either
are, or are not, relevant to other settings or countries but
produce no supporting evidence. Many studies also
Table 5: Factors influencing variation in cost-effectiveness
Influencing factor Examples
Epidemiological environment
Prevalence of condition Screening and referral programs for breast cancer
Incidence of condition Preventive measures for many injuries
Existence of competing risks of synergisms Some surgical interventions: among the very young or elderly, competing risks reduce the 
cost-effectiveness of some targeted interventions
Individual characteristics
Age Cancer treatment: more cost-effective for younger patients
Tendency to compliance Anti-hypertensive medication
Tendency to self-refer Diabetes control
Level of risk factors Hypertension and hyperlipdemia
Individual variation in values Attitude toward disability relative to risk of death; can lead to individual differences in 
intervention effectiveness
System characteristics
Local costs of non-traded inputs to health care system Real costs of care intensive interventions (such as hospitalisation after trauma) are low 
where wages are low, because most health care personnel are relatively immobile
Generalised systemic competence Cost-effectiveness at the margin of some interventions in a system with a low level of 
professionalism and capacity may be much higher than in more developed systems
Discount rate Where discount rates are high, interventions with payoffs well into the future (such as 
treatment of obesity) become relatively less attractive.
Source: adapted from Table 1–4 in Jamison [54].Page 7 of 10
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more difficult to transfer/generalise findings, unless the
prior level of existing services and infrastructure is clearly
specified, which was rarely the case.
At a basic level, consideration of the generalisability of
results would be improved if cost data was disaggregated
by price and utilisation level, to allow other analysts to
adapt results to their own circumstances. Alternatively an
investigation of how and why costs and effects vary within
the study site would allow some judgement about the
impact of independent variables on cost, effects and cost-
effectiveness in another setting. Table 5 is adapted from
Jamison et al [54]. and provides some examples of the fac-
tors influencing variation in cost-effectiveness of NCD
interventions. We suggest that researchers may find such
variables a useful starting point for contemplating the
design and analysis of future economic evaluations.
Given the paucity of evidence, the need to make decisions
and the likelihood of the leagues tables of cost-effective-
ness of health interventions in many regions of the world,
it is imperative that researchers explore issues to do with
generalisability within their own analysis. However, ana-
lysts have expressed concern that studies may be too con-
text specific and that a great deal of effort would need to
be spent on incorporating detailed information on local
costs, social concerns and political constraints for the
results/models to be generalised to another setting [55].
The response to the problem of poor quality context spe-
cific economic evaluations has been the arrival of the gen-
eralized cost-effectiveness analysis (CEA) [56]. Yet the
emergence of league tables showing the cost-effectiveness
of interventions for different regions has raised further
questions. What evidence is used to generate such results?
How are primary data be collected and if so by whom?
What is the role of existing data? And how applicable are
data from NCD economic evaluations conducted in
developed countries to developing countries? Only a very
small number of economic evaluations have been under-
taken on NCDs in developing countries in recent years
and, as we have shown, much of it is of dubious quality
and limited in scope. Decisions made on the basis of the
existing evidence base could result in the inefficient use of
scarce resources. Furthermore, given the apparent preoc-
cupation with the evaluation of communicable disease
interventions in developing countries, the case for ensur-
ing best practice in economic evaluations of NCDs is
given added urgency. This is not to say that the methods
for conducting economic evaluations of NCDs are any dif-
ferent from those applied to communicable disease.
Rather, we believe there is 'added' value from ensuring
that future economic evaluations undertaken in develop-
ing country settings are conducted in such a way as to
improve their internal and external validity.
If, in the absence of appropriate evidence, results from
developed countries are applied to developing country
settings via generalised cost-effectiveness analyses then
there needs to be a good understanding of which factors
have the most impact on the results. In the context of
NCDs, several parameters that have a large influence on
the results of studies might differ substantially between
developed and developing countries. For example in the
case of cancer, this includes the age-specific incidence of
cancer, all cause life expectancy, the age structure of the
population, cancer treatment effectiveness and the cost in
the absence of the preventive or screening intervention.
The clear advantage of the generalised cost-effectiveness
approach is that it can be presented in a way that can be
translated across different settings [56]. However it is also
acknowledged that 'global or regional cost-effectiveness
results may have limited relevance for local settings and
policy processes'. A way through this is via the 'contextu-
lisation' of generalized CEA to the country level. This is
achieved in a number of ways from assuming interven-
tions are done in a technically efficient way through to
modifying analyses to capture some local variations such
as differences in the use of labour [56]. Because the evi-
dence base for the economic evaluation of NCDs is so
weak, generalised CEA will have an increasingly impor-
tant role to play in public health decision making, so long
as local factors are fully taken into account.
Conclusion
What are the implications for future economic evalua-
tions in developing countries? First, future economic eval-
uations need to take a broader view and present data in a
transparent way. We have also identified some clear gaps
in the literature, particularly around injuries and strategies
for tackling the consequences of the emerging tobacco
epidemic in developing countries. Interventions to con-
trol chronic diseases such as diabetes mellitus and hyper-
tension are also under-represented. Second, more research
is needed which investigates the causes of variation
among cost, effects and cost-effectiveness data within and
between settings. Once this has been done, a third priority
is to undertake more work on assessing the transferability/
generalisability of existing and future evaluations within
and between settings and the results need to be explicitly
tested in different settings.
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